Is CELN-X in Diffused Large B-Cell?

I know docs and practice have kind of struggled with CELN-X or in myeloma, and I'm just wondering how it plays out in diffused large B-cell. How you compare the toxicity, convenience, et cetera, and how you right now, again, sort of putting aside CAR-T and by specifics of sequencing. Curious ideally how you would like to sequence these agents,. Also what your experience is with quality life on these agents, particularly CELn-X? Yes, I think we don't have clear guidelines, and it's only the experience.